Needham & Company Increases Regulus Therapeutics Price Target to $14.00 (RGLS)
Analysts at Needham & Company boosted their price target on shares of Regulus Therapeutics (NASDAQ:RGLS) to $14.00 in a research report issued to clients and investors on Friday, Analyst Ratings Network.com reports. Needham & Company’s target price would indicate a potential upside of 20.27% from the stock’s previous close.
Regulus Therapeutics (NASDAQ:RGLS) opened at 11.64 on Friday. Regulus Therapeutics has a 1-year low of $4.86 and a 1-year high of $12.89. The stock has a 50-day moving average of $8.96 and a 200-day moving average of $8.13. The company’s market cap is $486.3 million.
Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.13) by $0.02. Analysts expect that Regulus Therapeutics will post $-0.58 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Wedbush raised their price target on shares of Regulus Therapeutics from $17.00 to $19.00 in a research note on Friday, February 7th. Analysts at TheStreet upgraded shares of Regulus Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 20th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Regulus Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $15.75.
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing first-in-class drugs that target microRNAs to treat a range of diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.